Nobuo Kato

Nobuo Kato

Auto-generated profile, based on publicly available information

Nobuo Kato

The Institute of Scientific and Industrial Research, Osaka University, Osaka 567-0047, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2013 in ACS Chemical Biology
Verified
Journal Article
Closed access
MMManuela Molzan
Manuela Molzan
SKStefan Kasper
Stefan Kasper
LRLars Röglin
Lars Röglin
MSMalgorzata Skwarczynska
Malgorzata Skwarczynska
TSTakeshi Sassa
Takeshi Sassa
COChristian Ottmann
Christian Ottmann

1 January 2012 in Frontiers in Microbiology
Verified
Journal Article
Open access
YMYoshimi Matsumoto
Yoshimi Matsumoto
KKKunihiro Kaihatsu
Kunihiro Kaihatsu
KNKunihiko Nishino
Kunihiko Nishino
MOMiho Ogawa
Miho Ogawa
NKNobuo Kato
Nobuo Kato
AYAkihito Yamaguchi
Akihito Yamaguchi
(−)-Epigallocatechin-3-O-gallate (EGCG) has useful antiviral, antimicrobial, antitoxin, and antitumor properties. Previously, Mori et al. (2008) found that addition of long acyl chains (C16–18) to EGCG enhanced its anti-influenza virus activity up to 44-fold. The chemical stability of EGCG against oxidative degradation was also enhanced by acylation. We further evaluated the in vitro activity spectrum of the EGCG derivatives against a wide range of bacteria and fungi. A series of EGCG O-acyl derivatives were synthesized by lipase-catalyzed transesterification. These derivatives exhibited several-fold higher activities than EGCG, particularly against Gram-positive organisms. Antifungal MICs of the derivatives were also two to fourfold lower than those of EGCG. The activities of the EGCG derivatives against Gram-negative bacteria were not distinguishable from those of EGCG. Among the derivatives evaluated, MICs of dioctanoate and palmitate (C16) for 17 Staphylococcus aureus strains were 4–32 μg/ml, although MIC of EGCG for these 17 strains was ≥128 μg/ml. C16 demonstrated rapid bactericidal activity against methicillin-resistant S. aureus (MRSA) ATCC43300 at ≥16 μg/ml. The enhanced activity of C16 against S. aureus was supported by its increased membrane-permeabilizing activity determined by increased SYTOX Green uptake. The EGCG derivatives were exported in Escherichia coli using the efflux pump AcrAB–TolC. The tolC deletion mutant exhibited higher sensitivity to EGCG and the derivatives than wild-type. Addition of long alkyl chains to EGCG significantly enhanced its activities against several bacteria and fungi, particularly against S. aureus including MRSA. C16 might potentially become under specified circumstances an alternative or supplement to antibiotics and disinfectants in the future.

8 December 2015 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
DBDavid Bier
David Bier
MBMaria Bartel
Maria Bartel
KSKatharina Sies
Katharina Sies
SHSebastian Halbach
Sebastian Halbach
YHYusuke Higuchi
Yusuke Higuchi
COChristian Ottmann
Christian Ottmann

9 November 2005 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
TKTakashi Kasukabe
Takashi Kasukabe
JOJunko Okabe-Kado
Junko Okabe-Kado
NKNobuo Kato
Nobuo Kato
TSTakeshi Sassa
Takeshi Sassa
YHYoshio Honma
Yoshio Honma
Introduction: Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human breast carcinoma cell line MCF-7 as an experimental model system, we examined the growth-inhibitory effects of combinations of various agents and rapamycin to find the agent that most potently enhances the growth-inhibitory effect of rapamycin. Method: We evaluated the growth-inhibitory effect of rapamycin plus various agents, including cotylenin A (a novel inducer of differentiation of myeloid leukaemia cells) to MCF-7 cells, using either MTT assay or trypan blue dye exclusion test. The cell cycle was analyzed using propidium iodide-stained nuclei. Expressions of several genes in MCF-7 cells with rapamycin plus cotylenin A were studied using cDNA microarray analysis and RT-PCR. The in vitro results of MCF-7 cells treated with rapamycin plus cotylenin A were further confirmed in vivo in a mouse xenograft model. Results: We found that the sensitivity of rapamycin to MCF-7 cells was markedly affected by cotylenin A. This treatment induced growth arrest of the cells at the G1 phase, rather than apoptosis, and induced senescence-associated β-galactosidase activity. We examined the gene expression profiles associated with exposure to rapamycin and cotylenin A using cDNA microarrays. We found that expressions of cyclin G2, transforming growth factor-β-induced 68 kDa protein, BCL2-interacting killer, and growth factor receptor-bound 7 were markedly induced in MCF-7 cells treated with rapamycin plus cotylenin A. Furthermore, combined treatment with rapamycin and cotylenin A significantly inhibited the growth of MCF-7 cells as xenografts, without apparent adverse effects. Conclusion: Rapamycin and cotylenin A cooperatively induced growth arrest in breast carcinoma MCF-7 cells in vitro, and treatment with rapamycin and cotylenin A combined more strongly inhibited the growth of MCF-7 cells as xenografts in vivo than treatment with rapamycin or cotylenin A alone, suggesting that this combination may have therapeutic value in treating breast cancer. We also identified several genes that were markedly modulated in MCF-7 cells treated with rapamycin plus cotylenin A.

16 June 2009 in Organic Letters
Verified
Journal Article
Closed access
TTTomonobu Toyomasu
Tomonobu Toyomasu
MTMai Tsukahara
Mai Tsukahara
HKHiromichi Kenmoku
Hiromichi Kenmoku
MAMasahide Anada
Masahide Anada
HNHajime Nitta
Hajime Nitta
NKNobuo Kato
Nobuo Kato

27 January 2012 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
MNMotoyoshi Noike
Motoyoshi Noike
Chengwei LiuChengwei Liu
Chengwei Liu
YOYusuke Ono
Yusuke Ono
YHYoshimitsu Hamano
Yoshimitsu Hamano
TTTomonobu Toyomasu
Tomonobu Toyomasu
TDTohru Dairi
Tohru Dairi